Jeri Kim, VP, Head of Solid Tumor Clinical Development at Actinium Pharmaceuticals, Inc., shared a post on LinkedIn:
“I am thrilled to share that I am joining Actinium Pharmaceuticals, Inc. as VP, Head of Solid Tumor Clinical Development. Actinium Pharmaceuticals is dedicated to developing innovative and effective radioligand therapies for advanced cancers and delivering them to patients with significant unmet needs.
A sincere thank you to my former colleagues at iTeos Therapeutics for their partnership, encouragement, and trust throughout my time there. I learned not only about scientific innovation in a high-risk environment but also had the privilege of being associated with smart, dedicated, and brave individuals. Additionally, it was a real-world learning experience in the biotech ecosystem.
I would especially like to thank Dr. Christopher Logothetis and Dr. Timothy Thompson for their mentorship early on and support throughout my career. My team at Actinium Pharmaceuticals will be focused on advancing alpha radioligand therapies in metastatic castration resistant prostate cancer, which feels like a full circle back to my academic years at MD Anderson Cancer Center.
It is an honor to join Actinium Pharmaceuticals and support their mission of pioneering next-generation radioligand therapies to treat patients with high unmet needs. I am excited to begin this next chapter.”
More posts on OncoDaily.